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Summary
Purpose: To assess the cytogenetic effects in vitro and 
in vivo of a non-cytotoxic antitumor agent with biomodulator 
activity, 8-chloro-3’,5’ cyclic adenosine monophosphate (8-Cl-
cAMP).
Materials and methods:Cytogenetic effects of 8-Cl-cAMP 
where evaluated using the in vitro chromosome cytogenetic 
assay (CA) on human peripheral blood lymphocytes of healthy 
individuals and by bone marrow micronucleus assay in adult 
BALB/c mice.
Results: In the in vitro chromosome CA, 8-Cl-cAMP 
(in all respective doses; 1.5 and 15 µm) induced mitotic in-
hibition and premature centromere separation (PCS) but no 
chromosomal damage in cultured human peripheral blood 
lymphocytes. In the in vivo test, single intraperitoneal (i.p.) in-
jection of 8-Cl-cAMP in doses of 10, 80 and 150 mg/kg showed 
a dose-related effect on the frequency of micronuclei, detected 
in murine polychromatic erythrocytes (PCE).
Conclusion: The results of the present study show that 
genotoxicity of 8-Cl-cAMP has a different matrix of response
when comparing results in vitro and in vivo, suggesting that 
high metabolic activity in vivo is responsible for the clastogenic
potential of 8-Cl-cAMP. These comparative results indicate a
need of having an available battery of genotoxic tests in order to
evaluate possible cytogenetic effects of novel antitumor agents.
Key words: 8-Cl-cAMP, antitumor agents, micronuclei, pre-
mature centromere separation
Introduction
Interest on antitumor agents’ genetic toxicity has 
increased over the past years due to better patient treat-
ments, combinational therapies and increased survival 
rate vs. higher incidence of secondary tumors after pri-
mary therapies and genetic defects due to mutagenic 
activity on gonadal cells [1-3].
8-Cl-cAMP is a antitumor agent synthesized more 
than 2 decades ago, based on a strategy to reduce toxic-
ity to normal cells and increase specificity towards 
cancer cells by modulating the cells’ signaling pathways 
[4,5]. cAMP is implicated in the regulation of a variety 
of cell functions. The actions of cAMP and cAMP ana-
logues are supposed to be mediated by the cAMP-de-
pendent protein kinase protein kinase A (PKA). The 
differential activity of 8-Cl-cAMP towards protein ki-
nase isozymes expresses inhibition of cell growth, dif-
ferentiation and neoplastic reversion of a wide variety
of cancer cell lines [5,6].
PKA is an enzyme in mammalian cells, which is
present in two isoforms: PKA I and PKA II [5-7]. Struc-
turally, these isoforms are composed from catalytic and 
regulatory subunits. Every isoform in its composition
has two types of regulatory units by which it can be dif-
ferentially distinguished: regulatory subunit (R) I α and 
R I β, i.e. R I α and R I β go into the R I isoform and R II
α and R II β go into the R II isoform [7,8]. The occur-
rence of R I and R II types of regulatory units differenti-
ate by the phase of the cell cycle, and between cells of 
different tissues. Still, most abundant are the R I α and 
R II β subunits [7,8].
The isoforms of PKA can be also differentiated 
by their affi nity towards cAMP, subcellular distribution
and function [8]. On every regulatory subunit there are
2 places for cAMP attachment, the attachment place A 
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and the attachment place B. 8-Cl-cAMP as a specifi c 
cAMP analogue is attached on both places (A and B), 
the same as cAMP, but with different affi nity. With the 
strongest affi nity 8-Cl-cAMP is attached to place B on 
the R II subunit and for place A with the weakest. On the 
other hand 8-Cl-cAMP has a high affi nity towards place 
A on the R I subunit and moderate affi nity for place B. 
In micromolar concentrations 8-Cl-cAMP is connected 
only on the B place of the R II subunit, so that PKA II 
stays in the form of a holoenzyme, which, by a negative 
biofeedback pool, brings a decrease in the synthesis of 
PKA I. The antiproliferative activity of 8-Cl-cAMP is 
based on the decrease or downstream regulation of PKA 
I in malignant transformed cells [8-10].
In vivo 8-Cl-cAMP as a sole therapy has shown a 
good antitumor effect on xenografts of colorectal car-
cinoma, breast, ovarian and pancreas carcinoma, and 
in combination therapy it has shown that it can increase 
the antiproliferative capacity and antitumor activity of 
taxanes and cisplatin analogues [11-15].
The rationale for combination therapy comes 
from the overall knowledge of the mechanisms from 
individual action of these substances, i.e. 8-Cl-cAMP 
and taxanes in which a crucial role in the synergistic ac-
tion plays PKA. Taxanes are known for their genotoxic 
potential [16], but cAMP analogues have been rela-
tively underrepresented for their clastogenic potential 
in human and animal cells.
The aim of this study was to contribute to the 
characterization of the genetic toxicity of 8-Cl-cAMP 
by studying chromosomal damage in human lympho-
cytes and in the bone marrow of BALB/c mice. Chro-
mosomal aberrations are direct indications of genetic 
damage by various xenobiotics including antitumor 
agents. Therefore, the two cytogenetic endpoints, chro-
mosomal aberration test in vitro and micronuclei (MN) 
test in polychromatic erythrocytes (PCE) of mice in 
vivo serve as excellent markers to assess the genotoxic 
potential of 8-Cl-cAMP.
Materials and methods
Chemicals
For the cytogenetic analysis during the last 2 h 
of incubation colcemide was added to the medium in a 
concentration of 0.05 µg/ml. For the cytogenetic assay, 
the investigated substance 8-Cl-cAMP (Sigma Chemi-
cal Co., St. Louis, MO, USA; CAS No 41941-56-4) in 
doses of 1, 5 and 15 µM was added 40 h after the incu-
bation and stayed in culture to the end of cultivation (72 
h). A known clastogen, mitomycin C (Sigma Chemical 
Co., St. Louis, MO, USA; CAS No 50-07-7), was used 
as positive control at a dose of 0.15 µM using the same
protocol as for 8-Cl-cAMP.
Chromosome aberration analysis in human lympho-
cytes in vitro
Metaphase chromosome analysis for the detec-
tion of chromosomal aberrations (CAs) was performed 
according to conventional techniques [17]. Human
peripheral blood lymphocytes (PBLs 2×106 cells) ob-
tained from 10 healthy donors were isolated by density
gradient, cultured in 10 ml RPMI tissue culture medium
(Gibco, Grand Island, NY, USA) containing 20% fetal
bovine serum (inactivated), 1% phytohaemag glutinin,
glutamine 1 mM and 500 IU of penicillin and strepto-
mycin incubated at 37° C and 5% CO2 for 72 h. After 
48 h of incubation, the cultures were treated with 8-Cl-
cAMP dissolved in PBS. The dose levels of 8-Cl-cAMP 
were 1, 5 and 15 µM. The dose levels were estimated 
by the highest tolerant dose (15 µM) in phase I clinical
studies [18]. The positive control substance was mito-
mycin C at a dose of 0.15 µM. The lymphocyte cultures
were treated with 8-Cl-cAMP for 24 h. Chromosomes
were prepared for observation according to the con-
ventional hypotonic –Giemsa schedule. Scoring was
done by a single observer with randomized slides. CAs
were scored in 200 metaphases per sample according to
the classifi cation criteria suggested by Savage (1976)
[19]. All samples where pooled and the mean value was
analyzed. The number of aberrant metaphases, referred 
to the text as damaged cells, and the number of CAs
were counted.
Micronuclei analysis
The investigated substance was tested at 3 experi-
mental concentrations. The lowest concentration should 
correspond to its level in the environment, but, as this is a
synthetic substance, the level of 10 mg/kg of body weight 
(b.w.) was taken on the basis of postnatal growth toxicity
induced by 8-Cl-cAMP [20]. The median concentration
was established from the maximal tolerance dose, a dose
which shows clinical manifestation of mild toxicity (loss
of weight, diarrhea, ataxia, somnolence). The high con-
centration dose is a sublethal dose of 8-Cl-cAMP (150
mg/kg b.w.) based on preliminary toxicological investi-
gation (acute toxicity) on BALB/c mice. Experimental
design for both in vivo tests included 3 groups: positive
control, negative control and experimental groups. The
experimental groups were divided into 3 subgroups based 
on the chosen doses of 8-Cl-cAMP.
The negative control group was treated with nor mal
saline solution. A known mutagen, cyclophosphamide,
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at a dose of 60 mg/kg b.w. was used for the positive 
control group because of its known clastogenic and 
mutagenic properties [21]. Cyclophosphamide and 
8-Cl-cAMP were dissolved in normal saline solution 
immediately prior to i.p. administration and the volume 
injected was 0.1 ml/kg/b.w. All groups had equivalent 
numbers of animals per test. For the MN test 8 animals 
were used per dose/group (both sexes). We used BALB/
c mice of 6 weeks of age with an average weight of 19±2 
g. The animals were kept under uniform conditions, 
housed under 12/12 h photoperiod at constant tem-
perature (21° C) with free access to standard laboratory 
chow and water. Mice were sacrifi ced 24 h after single 
i.p. treatment, in accordance to the EEC convention 
guidelines. The frequency of MN in the bone marrow 
was detected according to the classical technique by 
Schmid and Tinwell [22,23]. Femoral cells were fl ushed 
out with fetal calf serum (Gibco, UK). The collected 
cells were sedimented by centrifugation (1800 rpm) 
and resuspended in fetal calf serum on microscopic 
slides. Before cells were fi xed in methanol for 15 min 
they were air-dried and then dipped in phosphate buf-
fer, pH 6.4. Slides were stained in a solution of acridic 
orange (12.5 mg/100 ml buffer) for 60 sec [23], were 
exposed to buffer for 10 min and then observed for the 
presence of MN in PCE. Data were summarized as the 
mean number of micronucleated PCE per 1000 PCE. In 
addition, the ratio between PCE and normochromatic 
erythrocytes (NCE) was also determined.
Statistical analysis
The clastogenic action of 8-Cl-cAMP was ana-
lyzed by using the analysis of variance (one way) and 
the x2 test.
Results
Table 1 shows the distribution of total aberrations
and related changes in the frequency of aberrant cells
induced by doses of 1.5 and 15 µM of 8-Cl-cAMP.
Results in Table 1 show that 8-Cl-cAMP didn’t induce
a statistically signifi cant difference in total CAs and 
in different chromatid type aberrations in PBLs when
compared with the negative control group.
Table 2 shows results concerning the occurrence
of premature centromere separation (PCS) in PBLs
induced by increasing doses of 8-Cl-cAMP. PCS is not 
a classical parameter of xenobiotic clastogenicity, but it 
can lead to chromosome instability and aneuploidy. To
address these fi ndings we estimated the frequency of 
PCS occurrence on one chromosome, more than one,
and on all chromosomes (Figure 1).
In Table 2 PCS occurrence is more determined 
by its distribution pattern than by the percentage of 
total metaphases with PCS. The highest dose of 8-Cl-
cAMP (15 µM) showed a shift from more than one
chromosome to be affected by PCS to the group where
all chromosomes are affected by PCS. Still, the overall
presence of PCS in the 15 µM group is decreased com-
pared with the 5 µM group, meaning that increasing
doses of 8-Cl-cAMP and the occurrence of PCS is a
specifi c phenomenon concentrated to the centromere
region of the affected chromosomes and not to 8-Cl-
cAMP cytotoxicity.
Table 1. Presentation of different chromatide type aberrations in peripheral blood lymphocytes of control groups and cells treated with
increasing doses of 8-Cl-cAMP
Total no.   No. of iso- Total no.
Concentration of cells Chromatid Gaps chromatid of aberrant Mitotic
analyzed breaks  breaks cells index
 (pooled) No. % No. % No. % No. % No./SD* %
Negative control
(A) 2013 12 0.59  21  1  7 0.35  40 1.98 92±7 9.2
1 µM
8-Cl-cAMP (B) 2005 13 0.64  21  1  7 0.35  41 2 30±5.3 3*
5 µM
8-Cl-cAMP (C) 2012 14 0.7  23  1.14  6 0.30  43 2.1 17±3.1 1.6*
15 µM
8-Cl-cAMP (D) 2000 15 0.75  28 28  9 0.45  52 2.6 7,5±2.2 0.7*
Positive control (E)
MMC 2000 76* 3.8 152*  7.6* 86* 4.3 314* 15.7 2±1.7 0.1*
0.15 µM
(A:B:C:D) without significant difference (NS)(A/B/C/D:E); *p <0.001, highly statistically significant difference of the negative control and experimental
groups compared to positive control (x2 test); The mitotic index represents the mean number of cells gone into mitosis based on 1000 cells scored per 
sample/subject; SD: standard deviation; MMC: mitomycin C
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In contrast to partially negative results in the CA 
test in vitro, the administration of 8-Cl-cAMP in vivo
showed an ability to induce MN in PCE of bone mar-
row of BALB/c mice (Table 3). Statistical analysis 
demonstrated a statistically highly signifi cant difference 
(p <0.001) in MN induction (4.88±0.35; 8.32±0.57; 
11.74±0.37) at all 3 concentrations of 8-Cl-cAMP (10, 
80 and 150 mg/kg b.w., respectively) over the nega-
tive control (2.04±0.28) (Table 3). Also, these results 
demonstrated a dose-response relationship between 
exposure to 8-Cl-cAMP and the frequency of MN in 
PCE. The ratio between PCE and NCE did not reveal 
any toxic effect of 8-Cl-cAMP on erythropoiesis.
Discussion
The results obtained in the in vitro study dem-
onstrated that 8-Cl-cAMP did not induce structural 
chromosomal damage in cultured lymphocytes, but 
induced a decrease in the mitotic index and induction
of premature centromere separation. These results
show a non clastogenic action of 8-Cl-cAMP with a
note of cytotoxicity seen as an alteration of centromere
dynamics or PCS. PCS was found in all doses. Also, the
fi ndings of chromosomal instability were accompanied 
by a decrease in the mitotic index. The signifi cance of 
dose-response relationship for the mitotic index indi-
cates that PCS may result from a comprised mitotic cell
cycle control machinery.
The results of the mouse study with acute in vivo
exposure was positive. MN induction due to 8-Cl-cAMP 
reached statistical signifi cance at all doses tested when
compared to the negative control group (Table 3).
The in vivo experimental results demonstrate a
correlation between 8-Cl-cAMP cytotoxicity and geno-
toxicity. One of the possible reasons is that the plateau
of overall cytogenetic changes already exists at the
maximal tolerated dose (MTD) dose level (80 mg/kg
b.w.) where animals clinically express signs of mild 
toxicity. Our results demonstrate genotoxic potential
Table 2. Comparative estimation of premature centromere separation (PCS) induction in control and experimental groups treated with
increasing doses of 8-Cl-cAMP
Concentration Average no. of PCS induced on PCS induced on PCS induced on Overall number of
(µM) analyzed mitoses less than 2 more than 2 all chromosomes mitoses with PCS
 chromosomes chromosomes
X±SD % X±SD % X±SD % X±SD % X±SD %
(pooled)
Negative 121±9.7 100 – – – – 2±1.41 1.65 2±1.41 1.65
control (K)
1 µM (A)
8-Cl-cAMP 110±10.2 100 23.7±2.8 21.5 10.1±1.2 9.2 0.2±0.4 0.18 33.8±3.3 31*
5 µM (B)
8-Cl-cAMP 125±10.5 100 41±3.2 32.8 19.4±2.2 15.5 / / 60.5±4.6 48.4*
15 µM (C)
8-Cl-cAMP 115±9.5 100 23±2.6 20 10±1.91 8.7 0.5±0.5 0.4 33.5±4.2 29.1*
*indicates statistically significant difference, p <0.001 (Student’s t-test was used for statistical analysis of the overall number of mitoses with PCS)
K:A* K:B* K:C*
A:B=* B:C=* A:C = non significant
SD: standard deviation
Table 3. Frequency of polychromatic erythrocytes (PCE) with
micronuclei (MN) induced by increasing doses of 8-Cl-cAMP
Treatment PCE with PCE/NCEb
(mg/kg) MN/1000 cellsa
Negative control/PBS 2.04±0.28 2.03±0.21
10 8-Cl 4.88±0.35c 2.10±0.27
80 8-Cl 8.32±0.57c 2.18±0.41
150 8-Cl 11.74±0.37c 1.87±0.35
Cyclophosphamide 60 19.4±3.75c 1.75±0.14
aeach treatment group contained 8 mice and 1000 PCE were examined per 
animal. Data indicate mean ± SD; bdata indicate percentage mean ± SD val-
ued on 1000 erythrocytes; cp <0.01, significantly different from the nega-
tive control results using x2 test; NCE: normochromatic erythrocytes
Figure 1. Metaphase nuclei showing premature 
separation in more than 2 chromosomes (arrows) induced by 8-
Cl-cAMP at a dose of 5 µM.
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of 8-Cl-cAMP on bone marrow cells of BALB/c mice 
strain considering the correlation between dose and ef-
fect in the MN test.
The results of previous preclinical investigations 
of 8-Cl-cAMP demonstrated a complicated action of 8-
Cl-cAMP in various tumor cell lines in vitro and in vivo
[24-27]. Based on the microarray expression profi les 
of 8-Cl-cAMP and 8-Cl-adenosine [28], and the dif-
ferential expression of genotoxicity in vivo and in vitro
we can conclude that 8-Cl-cAMP exerts a very complex 
cytotoxic, genotoxic and antiproliferative action in 
cancer and normal cells, i.e. 8-Cl-cAMP is active per se
and in part through its metabolite, 8-Cl-adenosine. In 
our in vitro experiment we used heat-inactivated serum 
in order to exclude serum metabolism of 8-Cl-cAMP. 
We found no clastogenic action in the cytogenetic test 
in the proposed dose regime. The doses were estimated 
by evaluating the neutral red uptake (data not shown) 
and literature data, where IC50 (50% growth inhibition) 
showed a 50% growth inhibition in doses of 1-25 µM 
for 19 cancer cell lines with no signs of toxicity [24]. 
These doses appear to be concentrations below those at 
which degradation by phosphodiesterase can take place 
[27, 29- 31] and that the growth–inhibitory effect is not 
due to cell killing. Still, the fi ndings of an increase in 
the frequency of MN in the highest dose and PCS in all 
doses confi rm that 8-Cl-cAMP at these doses can induce 
chromosomal instability.
8-Cl-cAMP can induce a specifi c chromosomal 
alteration, i.e. PCS. PCS is known as a parameter of 
chromosome instability leading to aneuploidy [32-35]. 
The induction of PCS (31, 47 and 29%, respectively) 
by all doses of 8-Cl-cAMP (1, 5 and 15 µM) was statis-
tically highly signifi cant (p <0.001) when compared to 
the control group (1.65%). Further analysis showed a 
distribution pattern of PCS induced by our investigated 
agent. This pattern is dependent on the dose. Still, there 
is no linear dose-effect correlation, i.e. at the highest 
dose (15 µM) we saw a decrease in the overall number 
of mitoses with PCS (Table 2). This suggests that 8-Cl-
cAMP induction of PCS is probably due to its action 
through a mechanism involving PKA-II proteins which 
are present at the centromere region [36].
Today’s clinical experience of 8-Cl-cAMP anti-
tumor activity comes from 3 phase I clinical trials. In-
vestigators have established that plasma concentration 
in the range of 1-5 µm of 8-Cl-cAMP can signifi cantly 
inhibit tumor proliferation, and that this effect is at-
tained at concentrations below the MTD, which gives a 
possibility to reduce toxicity and genotoxicity [37,38]. 
8-Cl-cAMP is especially potent in combination thera-
pies with other cytotoxic agents [39], as it does not 
increase their myelotoxic effect which is one of the 
main problems of combination therapies in oncology.
Similar fi ndings have also been recorded for the eryth-
rocyte line toxicity in preclinical toxicological studies,
i.e. 8-Cl-cAMP doesn’t suppress erythropoiesis, as our 
results show in the mouse model.
Prediction of potential carcinogens and risk as ses-
sment are mainly toxicological problems, and human
carcinogens - especially antitumor agents - are likely
to operate through multiple mechanisms [39-41]. Mu-
tational mechanisms can be proposed for most human
carcinogens, but clear evidence also exists that epigen-
etic mechanisms may be involved. PCS can be classi-
fi ed as an epigenetic alteration expressing chromosomal
instability leading to aneuploidy.
In studying a chemical, it is not uncommon to fi nd 
a positive chromosomal aberration test in vitro and a
negative test in vivo or vice versa, or even no evidence
for mutagenicity in a battery of genotoxicity tests [42].
Chromosome aberrations may indicate alterations in
cell homeostasis that are important in genome instability
i.e., interference with DNA replication or condensation
[20,42]. So, chromosomal instability by 8-Cl-cAMP as
detected in PCS in human lymphocytes may not be the
result of electrophilic interaction with DNA, but through
microtubular dynamics by utilizing PKA II [36]. Results
given by both tests may postulate that 8-Cl-cAMP has pro-
moter activity exerted on the basis of its metabolic level.
Numerous biochemical and molecular analyses have
shown that an increase in the expression of  3’, 5’ phos-
phodiesterases by 8-Cl-cAMP in vivo indicate a potential
for co-toxic activity of 8-Cl-cAMP metabolites. Still, these
metabolites, especially 8-Cl-adenosine, and new data for 
8-ATP show anticancer activity [25,29,37-41]. So, how do
our tests help evaluate the risk-benefi t ratio?
Biological effects of chemicals are dependent on
the dose and the dose rate at which chemicals reach the
target tissue. Even if 8-Cl-cAMP is shown to be a non
clastogen in human lymphocytes, the antitumor agent 
might enhance instability or PCS initiated by other 
chemicals. The results of the complex cytogenetic ac-
tivity of 8-Cl-cAMP show that in vitro/ in vivo cor-
relations are most important in preclinical and clinical
toxicological risk evaluations.
Our results of in vitro 8-Cl-cAMP genotoxicity
demonstrates that PCS is a parameter of chromosome
instability and should be evaluated solely as a parame-
ter of genotoxicity in future risk-benefi t assessments.
The results of 8-Cl-cAMP genotoxicity and the
anti-proliferative property of 8-Cl-cAMP to act through
various mechanisms per se and/or through its metabo-
lites in low but effective doses promise new pathways
for combination therapies that may be used in future
treatments of cancer patients.
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